How to best enable pharma innovation beyond the COVID-19 crisis
Innovating in response to public health challenges like COVID-19 does not always align well with pharmaceutical industry commercial models or shareholder expectations. More sustainable and scalable ways of incentivising innovation in response to infectious disease threats are needed.
26 May 2020